As China’s immuno-oncology market adapts to the ever-growing ranks of homegrown PD-1/L1-targeting agents, SinoCellTech has received approval for what will be the 17th product in the sector - but the first in its specific indication.
Finotonlimab A China IO Latecomer But First In Country For 1L HNSCC
SinoCellTech's PD-1 inhibitor finotonlimab has become the first immuno-oncology drug to be approved in China for first-line head and neck squamous cell carcinoma regardless of PD-L1 expression.
More from China
More from R&D
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
A decision from the FDA is due by 28 September.